Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • NCI Community Oncology Research Program

Sponsor

Alliance for Clinical Trials in Oncology

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT03609021

This phase III trial evaluates mammographic breast density in participants with hormone
receptor-negative breast cancer enrolled on study A011502. High breast density has been shown
to be a strong risk factor for developing breast cancer and decreasing breast density may
decrease the risk for breast cancer. Participants treated with aspirin may show reduced
breast density on a mammogram.

Intervention

Biospecimen Collection, Screening Mammography

Condition

Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative

Investigators

Marie Wood, MD

See list of participating sites